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Background: Oral and oropharyngeal squamous cell carcinomas (OSCC) are among the most common cancers.
The poor survival rate among oral cancer patients can be attributed to several factors, one of them being lack of
early detection. A key approach to this problem would be to detect potentially malignant lesion at their early stage.
Using the FISH technique, oral brush cytology slides can be an easy and rapid screening approach for malignant
cell detection. The present study was designed to detect hTERC and SOX2 amplifications in OSSC exfoliative tumor
cells and evaluate whether those two gene amplifications might serve as a supportive biomarker in early detection
and diagnosis of oral and oropharyngeal SCC.
Results: Brush biopsies were collected from exophytic and exulcerated oral and oropharyngeal lesions of the oral
cavity of 71 patients and 22 healthy controls. FISH techniques using a TERC-specific DNA probe and a SOX2 DNA
specific probe both combined with a centromere 3-specific control probe was performed on the cytology slides.
A 100 squamous epithelial cell nuclei of the smears per slide were analysed. As abnormal FISH pattern were
considered amplified and polyploid patterns.
From 71 brush biopsies of oropharynx and other locations in oral cavity analysed by FISH 49 were considered to be
abnormal (69%). The over representation of polyploidy and/or TERC/SOX2 amplification in tumour samples was
statistically significant when compared to controls (p = 0.01).
Conclusion: SOX2 and TERC gene amplifications are common in all squamous cell carcinomas and their detection
in early stages could be crucial for early detection and more accurate prognosis. Our study strongly suggests that
early detection by FISH on cytobrushed samples could be a possible non-invasive screening method even before a
tissue biopsy is performed.
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Oral and oropharyngeal squamous cell carcinomas
(OSCCs) are among the most common cancers, and a
major cause of moratlity, with approximately 400,000 new
cases and 200,000 deaths reported worldwide every year.
For more than a half of OSSC patients the overall survival
rate is only five years [1]. The poor survival rate among
oral cancer patients can be attributed to several factors,
including a lack of early detection. The established criteria* Correspondence: nadja.kokalj-vokac@ukc-mb.si
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article, unless otherwise stated.of disease evaluation are biopsy diagnosis, lymph node
involvement and stage, although they do not sufficiently
account for the variability in clinical outcome. A key solu-
tion to this problem would be to detect potentially malig-
nant lesions at an early stage. Tissue biopsy is performed
only when the lesions become symptomatic. New me-
thods are needed for the earlier detection of malignant
cells, as are genetic markers for assessing disease aggres-
siveness and prognosis. Exfoliative cytology is an easy,
non-invasive procedure and hence could be performed
even on the suspicious lesion. Performing FISH on oral
brush cytology slides can be a simple and rapid screening
tool for malignant cell detection. In our study, the rate ofntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ples using this noninvasive technique.
During the last two decades, several genome screening
approaches have been developed, including chromosome
comparative genomic hybridization (CGH) and array-CGH.
These techniques have made it possible to classify chro-
mosomal aberations at a high resolution, which can reveal
frequent copy number gains and losses. Many such copy
number aberrations harbor oncogenes or tumor suppres-
sor genes and have therefore emerged as predictive and
prognostic markers for tumors. Gains of chromosome
arms 1q, 3q, 3q 5p, 7p, 7q, 8q, 9q, 11q, 14q, 16p, 19q, and
20q and losses in 2p, 3p, 3p, 4q, 8p, 10p, 16q and 18q have
been detected in OSCC samples, and genes located in
those regions have been suggested as putative cancer-
associated genes that might be altered during oral car-
cinogenesis [2-5]. Various proto-oncogene amplifications
within critical regions have been detected, including TERT
at 5p15, EGFR at 7p12, MYC at 8q24, and CCND1 at
11q13 [2,6]. A gain in the 3q26 region, which contains the
hTERC and SOX2 genes, is frequently observed in various
squamous cell carcinomas of mucosal origin. The human
telomerase RNA component (hTERC) gene encodes an
RNA subunit of telomerase that maintains the length of
telomeres during cellular divisions and is activated in ma-
lignant diseases. TERC gene amplifications are described
in the development of various SCCs, such as those in the
larynx [7], cervix, esophagus and lungs. Our results, as
well those of other authors, obtained from cervical smears
have demonstrated that TERC gene amplifications cor-
relate with high-grade squamous intraepithelial lesions that
lead to invasive cervical cancer. SRY-related HMG-box 2
(SOX2) gene amplifications are also described in eso-
phageal and lung squamous cell carcinomas [8]. This
intronless gene encodes a member of the SOX family of
transcription factors which control the expression of a
number of genes involved in embryonic development, and
cooperate in the induction of pluripotent stem cells
[9-11]. Recently, independent studies have identified
SOX2 as a lineage-survival oncogene [12] in SCCs of
the lung based on an analysis of a large set of these
tumors using high-resolution and high-throughput
technologies [8,13]. In a study by Bass et al. [14], ampli-
fications of SOX2 were detected in 23% of lung SCCs
and 15% of esophageal SCCs. These amplifications re-
sulted in presumably oncogenic SOX2 overexpression.
Hussenet et al. [15] and Yuan et al. [16] detected SOX2
amplifications in lung SCCs at similar frequencies
(20%). Because 3q26 amplifications are also regularly
observed in oral cancer, the amplifications of the SOX2
gene could be an important diagnostic and prognostic
marker. Using combined array-CGH and tissue micro-
array analysis Freire’s et al. [3] detected a SOX2 gene
copy number gain in 52% of OSCC tumors in, which ahigh expression of SOX2 was suspected to be correlated
with gene copy number gain.
As described in our previous study on cervical preneo-
plastic lesions, TERC gene amplification is a high-risk
prognostic factor for cervical cancer [17] and is likely an
early event in tumorigenesis in squamous cell carcinoma.
Here, we investigated whether TERC and SOX2 are ap-
propriate markers for the early detection of OSCC. The
present study was designed to detect hTERC and SOX2
amplifications in OSSC exfoliative tumor cells and eva-
luate whether these two gene amplifications might serve
as a supportive bio-marker for the non-invasive detection
and diagnosis of oral and oropharyngeal SCC.
Results
The study included 71 patients, mostly males (n = 54,
76%). Both genders had a comparable median age at
diagnosis (Table 1). After study enrollment, 10 (0.14) pa-
tients died from their cancer and 14 (0.20) were lost to
follow-up. All patients had histologically verified squa-
mous cell carcinoma of the head and neck region, with
tumours located mainly in the oral cavity (36 cases, 0.51;
see Table 1 for details on tumour locations) or the oro-
pharynx (27 cases, 0.38). The tumours were predomin-
antly locally advanced cancers (48 stage IV cases, 0.68).
The substantial lymph node involvement (44 cases, 0.62)
may help explain the certain inconsistency between the
TNM classification and disease stage data in Table 1.
Distant metastases were present in the only two cases
(one in the lung, one in the brain, Table 1). All patients
received radical cancer treatment (surgery, chemothe-
rapy or radiotherapy), including two patients with a his-
tologically confirmed carcinoma in situ who had their
lesions surgically removed.
A total of 71 brush biopsies of the oropharynx and other
locations in the oral cavity were analyzed by FISH using
TERC, SOX2 and CEP-3 DNA probes. We considered
polyploid and/or amplified cases to be abnormal. The
intra and inter-tumor heterogeneity for the amplification
of TERC/SOX2 locus was observed. We detected different
FISH patterns in individual cases. A total of 49 of samples
(69%) were considered abnormal, including 28, 10 and
5 cases in which 4–6, 6–9 and > 9 chromosomes were
observed respectively. Twenty-seven of these were only
polyploid (Figure 1d,g,h); 22 were polyploid and amplified,
with CEP3: TERC/SOX2 FISH ratios that varied from
3:6–8, to 3–4:9–12 to 4:6–11 in the same tumor.
(Figure 1b,c,e,f ). Amplification only was detected in three
tumors. The FISH pattern CEP3:TERC/SOX2 was 2:>4 in
these tumors (Figure 1a). The over- representation of
polyploidy and/or TERC/SOX2 amplification in tumor
samples was statistically significant compared to controls
(p = 0.01, Table 2). When cancer samples were stratified
according to the disease stage the presence of polypolidy
Table 1 Clinical data of patients with OSCC
# (%) Median age at diagnosis (range) Observation time (range)
Women 17 (0.24) 57 (48–76) years 16 (3–27) months
Men 54 (0.76) 58 (36–84) years 14 (3–24) months
Deceased 10 (0.14)
Current status unknown 14 (0.2)






Floor of the mouth 13 (0.18)
Retromolar trigone 3 (0.04)
Lower alveolus 3 (0.04)
Buccal mucosa 2 (0.03)
Upper alveolus 1 (0.01)
Oropharynx 27 (0.38)
TNM classification
Tumour # (%) Lymph node status # (%) Distant metastasis # (%)
Tis 1 (0.01) N0 27 (0.38) M0 69 (0.97)




Disease stage # (%) Histologic grading # (%)
0 1 (0.01) Carcinoma in situ 2 (0.03)
I 4 (0.06) Grade 1 12 (0.17)
II 11 (0.15) Grade 2 45 (0.63)
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of how the stages were combined. However, when tumors
originating in the oropharynx were compared to tumours
from all other locations, polyploidy and/or amplifications
were observed at a significantly higher rate (p = 0.0442,
Table 2).
Total of 22 control samples were tested, all except one
were normal. In the abnormal case the smear was taken
from a healthy part of the oral cavity of a patient with
diagnosed OSCC.
Conclusion
In this study, we used two genes, SOX2 and hTERC,
which are considered potential OSCC marker genes, toevaluate the FISH/cytobrush technique a screening me-
thod for cancer cell detection in smears from the oral and
oropharyngeal cavity. Recurrent gene copy number aber-
rations are a frequent finding in OSCC and are belived to
be critically involved in tumor formation. Studies using
comparative genomic hybridisation and more recently,
array-CGH have identified the human chromosomal re-
gion 3q21-q29 has being associated with decreased overall
and disease-free survival in head and neck squamous cell
carcinoma patients [[18], Choi S, Myers JN: Molecular
pathogenesis of oral squamous cell carcinoma: im-
plications for therapy. J Dent Res 2008, 87(1):14–32.
Review]. Amplification of the genes located in this region,
particularly SOX2 and TERC, could be useful markers for
Figure 1 Different level SOX2 (a, b, c, d) and TERC gene (e, f, g, h) amplifications was shown in representative cells. The FISH pattern
CEP3 : SOX2 was 2 : >4 (a). Masive amplifications of SOX2 gene (b). Polyploidies and amplifications of SOX2 gene (c). Polyploidies of S0X2 gene
in pattern 9:9. Polyploidies and amplifications of TERC gene (e, f). Polyploidies of TERC gene (g, h). Patches of amplifications of TERC gene in
polyploid cell pointed by arrow (g).
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markers in oral brush smears performed in the oral and
oropharyngeal cavity.
We used cytobrush techniques to collect exfoliated
cells from OSCC lesions. This non-invasive technique
could be used as a suitable screening tool to detect sus-
picious oral cancer cases. Compared to tissue biopsy,
this techniques is also much more agreeable to the pa-
tient. The principle of the cytobrush technique was ap-
plied as early as 1951 [19] and has been used for RNA
sampling [20], although it has not been used in combin-
ation with FISH. We used these two same techniques in
a study of TERC gene amplifications in cervical cancer,
in which we suggested that FISH analysis for TERC
amplification should be included in the routine examin-
ation of cervical cancer as a screening method [17]. The
only problem in evaluating of the results obtained by
this method is that with brush sampling, malignant cells
are most likely not always collected in the smear. This
could be the reason for at least some of the normal re-
sults obtained for our 22 cases.
Two genes were chosen for the screening, SOX2 and
hTERC. An interphase FISH with a chromosome enu-
meration double-color DNA probe was used. Consistent
with tissue biopsies and histopathological diagnoses,
hTERC and SOX2 amplifications were not detected in
normal oral and oropharyngeal tissues, except in one
case, where the control smear was taken from the side
opposite the tumor in the oral cavity, which could have
been an actual positive case.
High SOX2 expression is detected in various oral
squamous cell carcinomas (e.g., oral cavity and tongue);such expression is thought to be activated through gene
copy number gain and is associated with poor prognosis
[3,21]. Maier et al. [22] studied, various types of SCCs
and detected SOX2 gene amplification in all SCC types.
They found that both the primary and the metastatic
tumor cell populations showed SOX2 amplification.
Their data suggest that SOX2 is targeted by relatively
early events during tumor development, and thus, they
postulated that activity of the SOX2 protein is more im-
portant in tumor initiation than tumor progression. In
our study, statistically similar levels of SOX2 and TERC
amplifications occurred in all stages of the disease re-
gardless of lymph node status and tumor classification
(Tables 1 and 2).
The TERC gene is a part of the telomerase complex,
which encodes the telomerase RNA template. TERC is
the most frequently observed amplified oncogene in cer-
vical precancerous lesions and linked to high-grade cer-
vical dysplasia and cancer [17,23-25]. High telomerase
expression can be explained by the amplification of the
TERC gene. The results of Lui Yu et al. [7] indicate that
telomerase reactivation is an early event in laryngeal car-
cinogenesis and is already detectable at the stage of pre-
cancerous laryngeal epithelial changes. According to our
results, showing that approximately 70% of OSSCs were
detected by FISH using brush smears, we would predict
that this technique could also be used to analyze the
precancerous lesions as a screening tool in patients with
suspected oral or oropharyngeal SCC.
In all histopathologically confirmed cases the same
amplification detection result was obtained for both
probes that were tested; i.e., when the TERC gene was
Table 2 FISH analysis of TERC/SOX2 loci vs. centromere 3 in OSCC patients according to the clinical characterization
Clinical characterization SOX2/TERC amplifications/polyploidy Odds ratio (95% confidence interval), p (two-tailed Fisher exact test)
Normal Polyploidy only Amplification and poliploidy Total abnormal
FISH results
Normal vs. total abnormal
FISH results
Normal vs. Polyploidy only Normal vs. amplification
with poliploidy
Controls 21 0 1 1
46.77 (5.91-370) 0.00 N/D2 (N/D2) 0.00 21.00 (2.56-455) 0.00
OSCC 22 27 22 49
Stage: I, II, III 8 7 8 15
1.29 (0.39 – 4.23), 0.78 1.25 (0.41-6.03) 0.76 1.00 (0.25-4.07) 1.00
Stage: IV 14 20 14 34
Stage: I, II 4 5 7 12
0.69 (0.17-2.77), 0.76 0.98 (0.18-5,13) 1.00 0.48 (0.09-2.34) 0.49
Stage: III, IV 18 22 15 37
Oropharynx 6 11 10 21
2.00 (0.59-6.93), 0.29 1.83 (0.47-7.46) 0.38 2.22 (0.53-9.52) 0.34
Outside oropharynx1 16 16 12 28
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sults confirm the observation of recurrent amplicons of
the 3q26 region, where both genes are located, as de-
scribed in various types of squamous cell carcinomas
[Knuutila S, Björkqvist AM, Autio K, Tarkkanen M, Wolf
M, Monni O, Szymanska J, Larramendy ML, Tapper J,
Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V,
Zhu Y: DNA copy number amplifications in human
neoplasms: review of comparative genomic hybri-
dization studies. Am J Pathol 1998, 152(5):1107–1123.
Review], [26]. Our results are in agreement with published
array-CGH data [5] showing that extra copies of chromo-
some 3 regin are often detected, including all or only part
of the 3q arm. Amplifications with a TERC/SOX2:CEP3
signal ratio >2 could be considered as abnormal results
where true amplicons are observed, and the FISH signal
occasionally appears as large dispersed areas of tested
probe (Figure 1b,g). We observed abnormal polyploid cells
in which almost the entire q arm of chromosome 3, in-
cluding the centromere included, existed in 3, 4, 5, 6, 9 or
more copies. From a prognostic point of view there is no
difference between cells that are polyploid only, polyploid
and amplified, or only amplified. Highly statistically sig-
nificant results were detected only between all tumor
cases and all controls.
Significantly different results were also obtained based
on the location of the tumor. A greater number of positive
cases were detected in the oropharynx compared to other
locations of OSSC. This could be related to the high rate
of HPV infection of esophageal carcinomas [27]. HPV
infection may be responsible for the underlying chromo-
somal instability that can create a cellular environment
where tetraploid cells can develop and proliferate. Tetra-
ploidy often precedes the development of aneuploidy [28].
Our data show that there was a heterogeneous FISH pat-
tern within and between tumors. These findings suggest
that the higher rate of abnormal results in oropharyngeal
tumors is related to polyploidies and HPV infections.
As we described in our previous study on cervical
preneoplastic lesions, TERC gene amplification is a high
risk prognostic factor for cervical cancer [17]. Maier
et al. [22] demonstrated that SOX2 gene amplification is
a common event in SCC of different organ sites, such as
lung and cervix, and that it appears to be an early event
in tumorigenesis. Cha et al. [29] analyzed the abundance
of copy number alterations and various gene amplifica-
tions in the dysplastic transitional area of oral squamous
cell carcinoma using array-CGH on fresh tissues. Those
results appear to support our hypothesis that SOX2
and TERC gene amplifications are prognostic markers
for OSSC and that amplifications are an early event in
tumorigenesis. In the future research, these observations
should be investigated on visible potentially precance-
rous lesions, such as erythroplakias.In conclusion, SOX2 and TERC gene amplifications
are common in all squamous cell carcinomas, and their
detection in early stages could be crucial for the detec-
tion and moreaccurate prognosis of OSCCs. Our study
strongly suggests that detection by FISH on cytobrushed
samples could be a non-invasive screening method even
before a biopsy is performed.
Methods
Tumors were classified according to location, lymph node
status and histological differentiation. Tumor cells were
collected from various locations within the oral cavity:
lips, tongue, mouth, larynx, hypopharynx and oropharynx,
(Table 1). The controls were normal healthy individuals or
buccal smears obtained from macroscopically uninvolved
mucosal areas of the patients.
Brush biopsies were collected from ulcerated exophytic
lesions of the oral cavity of 71 patients and 22 healthy
controls. Two cytological smears were obtained from the
area in question, and two were obtained from apparently
normal mucosa near the lesion area using a Cytobrush
Plus GT. A cytobrush cell collector was than rolled onto a
glass slide. Slides were first treated with a hypotonic solu-
tion (0.0375 mol/M KCl) for 10 min at 37°C and than
fixed with acetic acid and methanol (1:3) for 10 min at
room temperature (RT). Slides were then dried for 30 min
at 50°C and 30 min at 90°C, and than stored at −20°C until
use.
Two probes were used for FISH: a combined TERC-
specific DNA probe (RH17919 – 370 Kb- RH10606) in
red fluorescence emission and a centromere 3-specific
control probe (D3Z1) in green fluorescence emission (ON
hTERC 3q26/3q11 – Kreatech), or a SOX2 specific DNA
probe (D3S3416 – 800Kb - D3S3957) in green combined
with a centromere 3-specific probe in red (ZytoLight
SPEC SOX2/CEN3 Dual Colour Probe - ZytoVision).
FISH was performed on slides pre-treated using 0.05%
pepsin digestion for 30 min, fixation with 1% formalde-
hyde solution, and subsequent dehydration in an ethanol
series (70%, 90%, 100%) and followed by air-drying. Slides
were denaturated in 70% formamide for 3 min at 73°C,
and probes were denaturated for 10 min at 73°C. Ten mi-
croliters of probe was applied to each slide under the
22×22 mm plastic cover slip and hybridized overnight in a
moist chamber at 37°C.
The next day, the cover slips were gently removed and
the slides were washed in 0.4XSSC + 0.05% Tween for
3 min at 73°C and in 2XSSC + 0.05% Tween for 2–60 s
at RT. The slides were counter stained with DAPI and
embedded in an anti-fadent solution. Images were
acquired using an AxioImager.Z1 microscope (Zeiss,
Germany) equipped with optical filters for DAPI,
TRITC, and FITC (Chroma Technologies, Brattleboro,
VT, USA).
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ners using an x63 objective. The signals were evaluated by
screening the entire slide. Only morphologically abnormal
nuclei with FISH signals for both colors were counted.
Amplified and polyploid patterns were considered abnor-
mal FISH patterns. Amplified FISH patterns had cells with
two signals for CEP-3 and more than four signals for
3q26. Cells with more than 2 signals for CEP-3 and more
than two signals for 3q26 with a ratio of 1:1 were consi-
dered polyploid. We evaluated at least 100 nuclei per slide
and calculated the proportion of aberrant cells for each
specimen. Images were analyzed using Cytovision 2.81
Version A.I. software (Applied Imaging, UK) (Figure 1).
For statistical analysis odds ratios (OR) with 95% confi-
dence intervals (95%CI) were calculated, and the Fisher’s
exact test was used to compare groups. Statistical signifi-
cance was set at a P value less than 0.05.
This study was approved by the Ethics committee of
the University Clinical Centre Maribor, where the study
was performed, and signed informed consent was ob-
tained from each patient.
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